Extracellular Matrix Remodeling of the Umbilical Cord and Placenta in Preeclampsia
|ClinicalTrials.gov Identifier: NCT01931891|
Recruitment Status : Unknown
Verified July 2013 by Ayse Kirbas, Zekai Tahir Burak Women's Health Research and Education Hospital.
Recruitment status was: Recruiting
First Posted : August 29, 2013
Last Update Posted : August 30, 2013
Preeclampsia affects 2% to 8% of all pregnancies and is a major cause of maternal morbidity an mortality worldwide.Althought the primary pathology leading to preeclampsia is remain not known, complex pathophysiologic pathways and mechanisms have been described.
New blood vessels evolve during angiogenesis and vasculogenesis, two physiological processes, that play a crucial role in embryogenesis and placentation. Structural alterations in the human umbilical cord, maternal spiral arteries can cause adverse fetal consequences.Pre-eclampsia is accompanied by an extensive remodelling of the ECM of the umbilical cord. Pre-eclamptic Wharton's jelly contains higher amounts of glycosaminoglycans in comparison to control tissue.
Matrixmetalloproteinases (MMPs) are a family of proteolytic enzymes that degrade various components of the extracellular matrix (ECM). A Disintegrin And Metalloproteinases (ADAMs) and ADAMs with Thrombospondin motifs (ADAMTS) are proteinases closely related to Matrix Metalloproteinases (MMPs). Dysregulation of ADAMs and ADAMTS expression have been reported in different types of pathologies such as cancer, osteoarthritis, neurodegenerative inflammation or asthma.
The role of ADAMTS in the pathomechanism of pre-eclampsia has not been studied until now. We therefore decided to compare the ADAMTS composition of the umbilical cord and placenta from newborns of mothers with pre-eclampsia with those with normal pregnancy.
|Condition or disease|
|Alterations of ECM in Umbilical Cord ECM in Preeclampisa Alterations of ECM in Placenta in Preeclampisa|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Observational Model:||Case Control|
|Study Start Date :||July 2013|
|Estimated Primary Completion Date :||February 2014|
|Estimated Study Completion Date :||July 2014|
- severe preclampsia [ Time Frame: 34 weeks ]
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01931891
|Contact: ayse kirbas, email@example.com|
|Zekai Tahir Burak Maternity Hospital||Recruiting|
|Contact: nuri danisman, md 306-5000|
|Principal Investigator: ayse kirbas, md|
|Principal Investigator:||ayse kirbas, md||zekai tahir burak hospital|